Medicus Pharma MDCX 深 沪
已收盘 10-09 16:00:00 美东时间
0.0921
-0.010
-9.62%
华盛通- 最 高0.0948
- 今 开0.0865
- 成交量 1733.22万股
- 最 低 0.084
- 昨 收 0.1019
- 总市值 660.45万
- 52周最高 2.78
- 市盈率 静 --
- 换手率 24.17%
- 52周最低 0.084
- 委 比 -63.93%
- 总股本 7171.00万
- 历史最高 8.94
- 量 比 3.76
- 振 幅 10.60%
- 历史最低 0.084
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
Medicus Pharma Ltd. (NASDAQ:MDCX) shares fell 24.22% to $0.12 in after-hours trading Wednesday after the company announced a 50-to-1 consolidation of its common shares. Medicus Pharma is a biopharmaceutical company. The Share Consolidation The consolidation will take effect Oct. 12, with every 50 co...
10-08 15:28
Medicus Pharma announces major share consolidation plan
Medicus Pharma Ltd ( ($MDCX) ) has provided an update. Medicus Pharma Ltd. will...
10-08 04:31
Medicus Pharma shares are trading lower after the company announced a 50-for-1 stock split.
Medicus Pharma shares are trading lower after the company announced a 50-for-1 stock split.
10-08 04:24
Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. ...
09-29 19:31
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Medicus Pharma Ltd. (NASDAQ:MDCX) on Monday announced it will concentrate all future internally sponsored clinical development for its SkinJect asset exclusively on Gorlin syndrome patients presenting with multiple basal cell carcinoma lesions, concluding further development in sporadic nodular basa...
09-21 19:32
Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock
On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between the Company and Yorkville (the "SEPA"), effective as of such date. Pursuant to the SEPA, the Company ...
09-14 20:13
430亿美元买入、10亿美元卖掉，亏吗？
（来源：抗体圈） 刚刚，辉瑞与加拿大生物技术公司Medicus Pharma达成了一项最高可达10亿美元的授权协议。 被摆上货架的，是今年3月刚刚被辉...
09-04 17:23
超10亿美元！辉瑞终止的CD228 ADC获新东家
（来源：药研网） 9月3日，Medicus Pharma向美国SEC提交文件披露，公司通过其全资子公司Medicus Pharma Inc.，与辉瑞...
09-04 17:14
辉瑞曾放弃的这款药，正在逆袭！
近日，辉瑞与加拿大小型生物科技公司Medicus Pharma达成了一项共同开发与许可协议，将此前已终止研发的ADC候选药物PF-08046031（又名CD2...
09-04 16:34
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin. • Medicus Pharma stock is testin...
09-04 01:17
